TenX Biopharma is conducting clinical trials in cutaneous T-cell lymphoma, peripheral T-cell lymphoma, metastatic melanoma and metastatic renal cell carcinoma.
Zanolimumab is our lead product. It is a fully human anti-CD4 monoclonal antibody. Read more 
July 14th, 2010
PHASE II ZANOLIMUMAB TRIAL DATA IN PTCL PATIENTS PUBLISHED
Results were published in the British Journal of Haematology for a Phase II trial of zanolimumab (HuMax-CD4) treatment
in relapsed or refractory non-cutaneous peripheral T cell lymphoma patients.
May 6th, 2010
TENX BIOPHARMA TO PRESENT AT BIO 2010 IN CHICAGO
CEO of TenX Biopharma, Inc., Gardiner F. Smith, presented at the international BIO conference held in Chicago, May 3rd-6th.
April 29th, 2010
TENX BIOPHARMA TO CONDUCT CLINICAL STUDY WITH THE NATIONAL CANCER INSTITUTE
TenX Biopharma, Inc., announced today it has signed a collaboration agreement with the National Cancer Institute (NCI) to conduct an
investigator sponsored Phase II clinical trial.